EGFR L858R x EGFR exon 20 x EGFR-Ex19del x EGFR-G719X x EGFR T790M

Primary objective: To evaluate the safety of BEBT-109 combined with pemetrexed and carboplatin or cisplatin as first-line treatment for locally advanced, recurrent or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. Secondary objective: To evaluate the efficacy of BEBT-109 combined with pemetrexed and carboplatin or cisplatin as first-line treatment for locally advanced, recurrent or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations; To evaluate the pharmacokinetic characteristics of BEBT-109 combined with pemetrexed and carboplatin or cisplatin as first-line treatment for locally advanced, recurrent or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations.